Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Safety Alerts and Recalls

Pfizer Expands Recall to All Lots of Chantix Due to Nitrosamine Impurity

Brian Park, PharmD

September 17, 2021

The recalled lots of Chantix were distributed nationwide to wholesalers and distributors in the United States and Puerto Rico from May 2019 to September 2021.

Drugs in the Pipeline

Bamlanivimab Plus Etesevimab Authorized for Postexposure Prophylaxis for COVID-19

Brian Park, PharmD

September 17, 2021

Postexposure prophylaxis with bamlanivimab plus etesevimab is not a substitute for vaccination against COVID-19.

Drugs in the Pipeline

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

Brian Park, PharmD

September 17, 2021

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot.

Drugs in the Pipeline

AbbVie Seeks Approval of Upadacitinib for Ulcerative Colitis

Brian Park, PharmD

September 16, 2021

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.

News

Exkivity Approved for EGFR Exon 20 Insertion+ NSCLC

Brian Park, PharmD

September 16, 2021

Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

News

Brukinsa Gets Accelerated Approval for Marginal Zone Lymphoma

Brian Park, PharmD

September 15, 2021

The approval was based on data from 2 single-arm clinical trials in adults with relapsed or refractory marginal zone lymphoma who have received at least 1 anti-CD20-based regimen.

Drugs in the Pipeline

Linzagolix NDA Submitted for Uterine Fibroid Treatment

Brian Park, PharmD

September 15, 2021

The NDA submission is supported by data from the phase 3 PRIMROSE 1 and PRIMROSE 2 studies, along with data from the 76-week post-treatment follow-up study.

Drugs in the Pipeline

Study Evaluating Ampreloxetine for Neurogenic Orthostatic Hypotension Misses Endpoint

Brian Park, PharmD

September 15, 2021

The phase 3 study was evaluating the efficacy and safety of ampreloxetine for the treatment of symptomatic neurogenic orthostatic hypotension in patients 30 years of age and older.